Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

This file contains death counts and death rates for drug overdose, suicide, homicide and firearm injuries at the United States national level (additional datasets exist for other levels of geography). The data is grouped by 3 different time periods including monthly, yearly, and trailing twelve months. Please see data dictionary for intents and mechanisms included in each measure.

ObjectiveU.S. drug-related overdose deaths and Emergency Department (ED) visits rose in 2020 and again in 2021. Many academic studies and the news media attributed this rise primarily to increased drug use resulting from the societal disruptions related to the coronavirus (COVID-19) pandemic. A competing explanation is that higher overdose deaths and ED visits may have reflected a continuation of pre-pandemic trends in synthetic-opioid deaths, which began to rise in mid-2019. We assess the evidence on whether increases in overdose deaths and ED visits are likely to be related primarily to the COVID-19 pandemic, increased synthetic-opioid use, or some of both.MethodsWe use national data from the Centers for Disease Control and Prevention (CDC) on rolling 12-month drug-related deaths (2015–2021); CDC data on monthly ED visits (2019-September 2020) for EDs in 42 states; and ED visit data for 181 EDs in 24 states staffed by a national ED physician staffing group (January 2016-June 2022). We study drug overdose deaths per 100,000 persons during the pandemic period, and ED visits for drug overdoses, in both cases compared to predicted levels based on pre-pandemic trends.ResultsMortality. National overdose mortality increased from 21/100,000 in 2019 to 26/100,000 in 2020 and 30/100,000 in 2021. The rise in mortality began in mid-to-late half of 2019, and the 2020 increase is well-predicted by models that extrapolate pre-pandemic trends for rolling 12-month mortality to the pandemic period. Placebo analyses (which assume the pandemic started earlier or later than March 2020) do not provide evidence for a change in trend in or soon after March 2020. State-level analyses of actual mortality, relative to mortality predicted based on pre-pandemic trends, show no consistent pattern. The state-level results support state heterogeneity in overdose mortality trends, and do not support the pandemic being a major driver of overdose mortality.ED visits. ED overdose visits rose during our sample period, reflecting a worsening opioid epidemic, but rose at similar rates during the pre-pandemic and pandemic periods.ConclusionThe reasons for rising overdose mortality in 2020 and 2021 cannot be definitely determined. We lack a control group and thus cannot assess causation. However, the observed increases can be largely explained by a continuation of pre-pandemic trends toward rising synthetic-opioid deaths, principally fentanyl, that began in mid-to-late 2019. We do not find evidence supporting the pandemic as a major driver of rising mortality. Policymakers need to directly address the synthetic opioid epidemic, and not expect a respite as the pandemic recedes.

The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). From this collection, the NHCS contributes data that may inform emerging national health threats such as the current opioid public health emergency. The 2022 - 2024 NHCS are not yet fully operational so it is important to note that the data presented here are preliminary and not nationally representative.

The data are from 24 hospitals submitting inpatient and 23 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from October 1, 2022–September 30, 2024. Even though the data are not nationally representative, they can provide insight into the use of opioids and other overdose drugs. The NHCS data is submitted from various types of hospitals (e.g., general/acute, children’s, etc.) and can show results from a variety of indicators related to drug use, such as overall drug use, comorbidities, and drug and polydrug overdose. NHCS data can also be used to report on patient conditions within the hospital over time.

This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

To: State, territorial, tribal, and local policymakers and administrators of agencies and programs focused on child, youth, and family health and well-being

Dear Colleagues,

Thank you for your work to support children, youth, and families. Populations served by Administration for Children and Families (ACF)-funded programs — including victims of trafficking or violence, those who are unhoused, and young people and families involved in the child welfare system — are often at particularly high risk for substance use and overdose. A variety of efforts are underway at the federal, state, and local levels to reduce overdose deaths. These efforts focus on stopping drugs from entering communities, providing life-saving resources, and preventing drug use before it starts. Initiatives across the country are already saving lives: the overdose death rate has declined over the past year but remains too high at 32.6 per 100,000 individuals.

Fentanyl, a powerful synthetic opioid, raises the risk of overdose deaths because even a tiny amount can be deadly. Young people are particularly at risk for fentanyl exposure, driven in part by widespread availability of counterfeit pills containing fentanyl that are marketed to youth through social media. While overdose deaths among teens have recently begun to decline, there were 6,696 deaths among adolescents and young adults in 2022 (the latest year with data available)[1], making unintentional drug overdose the second leading cause of death for youth ages 15—19 and the first leading cause of death among young adults ages 20-24.[2]

Often these deaths happen with others nearby and can be prevented when opioid overdose reversal medications, like naloxone, are administered in time. CDC’s State Unintentional Drug Overdose Reporting System dashboard shows that in all 30 jurisdictions with available data, 64.7% of drug overdose deaths had at least one potential opportunity for intervention.[3] Naloxone rapidly reverses an overdose and should be given to any person who shows signs of an opioid overdose or when an overdose is suspected. It can be given as a nasal spray. Studies show that naloxone administration reduces death rates and does not cause harm if used on a person who is not overdosing on opioids. States have different policies and regulations regarding naloxone distribution and administration. Forty-nine states and the District of Columbia have Good Samaritan laws protecting bystanders who aid at the scene of an overdose.[4]

ACF grant recipients and partners can play a critical role in reducing overdose deaths by taking the following actions:

Stop Overdose Now

(U.S. Centers for Disease Control and Prevention)

Integrating Harm Reduction Strategies into Services and Supports for Young Adults Experiencing Homelessness (PDF) (ACF)

Thank you for your dedication and partnership. If you have any questions, please contact your local public health department or state behavioral health agency. Together, we can meaningfully reduce overdose deaths in every community.

/s/

Meg Sullivan

Principal Deputy Assistant Secretary

[1] Products - Data Briefs - Number 491 - March 2024

[2] WISQARS Leading Causes of Death Visualization Tool

[3] SUDORS Dashboard: Fatal Drug Overdose Data | Overdose Prevention | CDC

[4] Based on 2024 report from the Legislative Analysis and Public Policy Association

(PDF). Note that the state of Kansas adopted protections as well following the publication of this report.

Metadata-only record linking to the original dataset. Open original dataset below.

This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

This file contains death counts and death rates for drug overdose, suicide, homicide and firearm injuries by census tract of residence (additional datasets exist for other levels of geography). The data is grouped by 2 different time periods including yearly and trailing twelve months. Please see data dictionary for intents and mechanisms included in each measure.

When there are 1-9 deaths in an area, CDC uses a Bayesian model to calculate rates. A Bayesian model is a type of statistical model often used in geographic analysis. This model can improve stability of the rates in lower population areas and protects privacy by taking into account information from neighboring areas.

Data on prescription drug use in the past 30 days in the United States, by sex, race and Hispanic origin, and age group. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey. Search, visualize, and download these and other estimates from a wide range of health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

Data on prescription drug use in the past 30 days in the United States, by sex, race and Hispanic origin, and age group. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

Data on use of selected substances in the past 30 days among 12th graders, 10th graders, and 8th graders in the United States, by sex and race. Data are from Health, United States. Source: Monitoring the Future, Institute for Social Research, University of Michigan, supported by National Institutes of Health, National Institute on Drug Abuse. Search, visualize, and download these and other estimates from over 150 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

This file contains death counts and death rates for drug overdose, suicide, homicide and firearm injuries by county of residence (additional datasets exist for other levels of geography). The data is grouped by 2 different time periods including yearly and trailing twelve months. Please see data dictionary for intents and mechanisms included in each measure.

When there are 1-9 deaths in an area, CDC uses a Bayesian model to calculate rates. A Bayesian model is a type of statistical model often used in geographic analysis. This model can improve stability of the rates in lower population areas and protects privacy by taking into account information from neighboring areas.

This repository includes data from the Health Resources & Services Administration's Area Health Resources Files (years 2000, 2004-2019), CDC Wonder, National Conference of State Legislatures, and the Drug Enforcement Agency's Automation of Reports and Consolidated Orders System (ARCOS).

Please cite the following publication when using this dataset:

KN Griffith, Y Feyman, SG Auty, EL Crable, TW Levengood. (in press). County-level data on U.S. opioid distributions, demographics, healthcare supply, and healthcare access, Data in Brief.

These data were originally collected for the following research article:

Griffith, KN, Feyman, Y, Crable, EL, & Levengood, TW. (2021). “Implications of county-level variation in U.S. opioid distribution.” Drug and Alcohol Dependence 219: e108501. https://doi.org/10.1016/j.drugalcdep.2020.108501

According to Cognitive Market Research, the Global Opioids Market Size was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

  The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
  The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
  The hospital pharmacies had a market share of about XX% in 2023.
  The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
  The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
  The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
  North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Market Dynamics of the Opioids

Rising prevalence of chronic pain conditions globally

The increased prescription of painkillers during post-operative procedures and an increase in patients with terminally chronic pain or diseases including HIV, and severe cough brought on by lung infections are two causes that are anticipated to increase opioid use as a pain reliever. Chronic pain affects an estimated 20% of the global population, with conditions such as arthritis, cancer, and lower back pain contributing to the growing demand for effective pain management solutions. In the past, it resulted in a demand surge for opioids and boosted growth. Another factor for the growth of the opioid drug market is the spike in the number of surgeries. According to the National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention (CDC) in 2019, the prevalence of high-impact chronic pain in the United States was 7.4 percent.

(Source-https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf)

The aging population’s vulnerability is at high risk of chronic diseases such as cardiovascular diseases, arthritis, and cancer due to the high comorbid conditions. Declining fertility and mortality rates are some factors contributing to the geriatric population's rise. The impact of chronic pain increases with age and is highest among adults aged 65 years and above. Therefore, the rising geriatric population is anticipated to increase the demand for opioid drugs to manage chronic pain. According to the World Health Organization (WHO), the geriatric population increased from 1.0 million in 2020 to 1.4 million in 2021.

(Source-https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Opioid addiction and its side effects pose significant challenges to the market

One of the major challenges for this market is the high potential for abuse and addiction, physicians have scaled back their pain management prescriptions, decreasing global scales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers. The patient may become tolerant and need more and more drugs to achieve the effect of smoothing the pain. Moreover, using opioids for an extended period can develop a dependency, and after leaving the drug, the patient may suffer from withdrawal symptoms such as anxiety, irritability, drug cravings, tremors (shaking), and others. The heightened regulatory scrutiny has resulted in stricter guidelines for prescribing opioids, impacting accessibility for patients in genuine need of pain relief. Regulatory changes often aim to strike a balance between ensuring access for patients and preventing misuse. The forecasted period illustrates a decrease in the opioid market growth due to the adversities and the negative effects of opioids. Researchers and experts have considered this and are making constant efforts to reduce and minimize the negative side effects of opioids. As per the record, drug overdose in the year 2018, had 657 deaths.

(Source-https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-august-2018/download)

Furthermore, the Millennium Health's Signals report (2020) revealed that there was a rise in non-prescribed fe...

Users can quickly get statistics on a variety of health topics, including: accidents, mortality, childbirth, anemia, drug use and marriage. Background FastStats is part of the Centers for Disease Control and Prevention and provides quick statistics on a variety of public health topics. User Functionality From an alphabetical list, users can click on a specific topic of interest and have access to the basic statistics. From there, users can click on the source of the statistic to get more information. Users can also view state and territorial data. Data Notes Each data source and it s year are clearly identified. For most topics, the most recent data is from 2009, but data varies by topic. Site was last updated in March-2009.

Characteristics associated with low availability of treatment facilities and high rates of opioid overdose mortality were analyzed using a cross-sectional analysis design that combined county-level data from January 1, 2017, to December 31, 2021. Data for 3,130 counties in 50 states and Washington D.C. from several sources were accessed through PolicyMap, including American Community Survey (ACS), the Centers for Disease Control and Prevention (CDC), the United States Bureau of Labor Statistics (BLS), and the Substance Abuse and Mental Health Services Administration (SAMSHA).

"Using ED data to track trends in nonfatal drug overdoses is a critical strategy for expanding overdose surveillance and tailoring prevention resources to populations most affected, including initiation of medication-assisted treatment in ED settings and subsequent linkage to care for substance use disorders." - Nonfatal Drug Overdoses Treated in Emergency Departments — United States, 2016–2017, CDC MMWR Weekly / April 3, 2020 / 69(13);371–376 - https://www.cdc.gov/mmwr/volumes/69/wr/mm6913a3.htmNotes:As of April 2019, this map contains the most recent data available at the sub-county level for deaths (2012-2016), hospitalizations (2012-2015) and emergency room visits (2011-2015).All data comes from the New Mexico Department of Health Indicator Based Information System (NM-IBIS)Click on individual map layer items below ("Layers") for information about sources and methods for each data set.For Hospitalization and Emergency Room data, three NM hospitals do not report: 2 Indian Health Service Hospitals in northwestern New Mexico, and the Veteran's Administration Hospital in Albuquerque.

Data on use of selected substances in the past 30 days among 12th graders, 10th graders, and 8th graders in the United States, by sex and race. Data are from Health, United States. Source: Monitoring the Future, Institute for Social Research, University of Michigan, supported by National Institutes of Health, National Institute on Drug Abuse. Search, visualize, and download these and other estimates from a wide range of health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

Number of deaths in the United States caused by Substance Use Disorders (SUD) and all other causes from 2005 to 2017.

Health, United States is the report on the health status of the country. Every year, the report presents an overview of national health trends organized around four subject areas: health status and determinants, utilization of health resources, health care resources, and health care expenditures and payers.